Inflammatory Markers in Severity of Intracerebral Hemorrhage II: A Follow Up Study

Jacob E. Bernstein 1, Jonathan D. Browne 2, Paras Savla 1, James Wiginton IV 1, Tye Patchana 1, Dan E. Miulli 1, Margaret Rose Wacker 1, Jason Duong 3

1. Neurosurgery, Riverside University Health System Medical Center, Moreno Valley, USA 2. School of Medicine, California University of Science and Medicine, Colton, USA 3. Neurosurgery, Arrowhead Regional Medical Center, Colton, USA

Corresponding author: Jacob E. Bernstein, jacobebernstein@gmail.com

Abstract

Introduction

Spontaneous intracerebral hemorrhage (ICH) results in significant morbidity and mortality. The pathogenesis of brain injury after ICH is thought to be due to mechanical damage followed by ischemic, cytotoxic, and inflammatory changes in the underlying and surrounding tissue. Various inflammatory and non-inflammatory biomarkers have been studied as predictors and potential therapeutic targets for intracerebral hemorrhage. Our prior study showed an association with low vascular endothelial growth factor (VEGF) levels and increased mortality. This current study looks to expand on our prior results and will look at the relationship between tumor necrosis factor alpha (TNFα), C-reactive protein (CRP), VEGF, Homocysteine (Hcy), and CRP to albumin ratio (CAR) in predicting outcomes and severity in spontaneous intracerebral hemorrhage.

Methods

We conducted a retrospective chart review of patients with spontaneous intracerebral hemorrhage with TNFα, CRP, VEGF, Hcy levels drawn on admission. Albumin and CRP levels on admission were used to calculate CAR. Ninety-nine patients were included in the study. Primary outcomes included death, early neurologic decline (END), and hemorrhage size. Secondary outcomes included late neurologic decline (LND), Glasgow Coma Scale (GCS) on admission, GCS on discharge, ICH score, change in hemorrhage size, need for surgical intervention, and length of ICU stay.

Results

A total of 99 patients were included in this study, with 42% requiring surgical intervention and an overall mortality of 16%. Basal ganglia hemorrhage was seen in 41% of patients. Hcy and CAR were significantly correlated with ICH size in basal ganglia patients (r=0.36, p=0.03; r=0.43, p=0.03, respectively). CAR was significantly correlated with ICH score (r=0.33, p=0.007874). Admission VEGF levels less than 45 pg/ml had 8.4-fold increase in mortality (odds ratio [OR] 8.4545, p=0.0488). Patients with TNFα levels greater than 1.40 pg/ml had a 4.1-fold increase in mortality (OR 4.1, p=0.04)

Conclusion

Our study demonstrated that low levels (<45 pg/ml) of VEGF were associated with an 8.4-fold increase in mortality, supporting the neuroprotective effect of this protein. Elevated Hcy and CAR levels were associated with an increase in hemorrhage size in patients with basal ganglia hemorrhages. TNFα levels greater than 1.40 pg/ml were associated with a 4.1-fold increase in mortality, and this together with CAR being correlated with increased hemorrhage size and ICH score further demonstrate the inflammatory consequences after intracerebral hemorrhage. Future studies directed at lowering CRP, TNFα, and Hcy and/or increasing VEGF in intracerebral hemorrhage patients are needed and may be beneficial.

Categories: Neurology, Neurosurgery

Keywords: intracerebral hemorrhage, c-reactive protein, tnf alpha, homocysteine, vegf angiogenesis

Introduction

Spontaneous intracerebral hemorrhage (ICH) accounts for 10–20% of all strokes and has a higher morbidity and mortality than ischemic stroke, with 30-day mortality rates of 37-52% [1,2]. Medical management is the primary treatment modality and consists primarily of airway protection, oxygenation, tight blood pressure control, and correction of coagulopathy. Surgical intervention has limited efficacy compared to medical management and is often reserved for large hemorrhages causing mass effect or for intraventricular hemorrhage causing hydrocephalus. The pathogenesis of brain injury after ICH is thought to be due to mechanical damage followed by ischemic, cytotoxic, and inflammatory changes in the underlying and
surrounding tissue [1,2]. There has been much interest in utilizing biomarkers in order to predict outcomes and hopefully develop new therapies for stroke prevention and management. Biomarkers such as tumor necrosis factor alpha (TNF-α), C-reactive protein (CRP), homocysteine (Hcy), and vascular endothelial growth factor (VEGF) have previously been associated with differential findings in ischemic and hemorrhagic stroke [5-21]. Our prior investigation into these markers in 2018 found an association between low VEGF and increased mortality. There was also a non-significant trend in hemorrhage size and mortality with elevated levels of CRP and homocysteine. However, that study was limited secondary to its small size [21]. In addition to the previous markers, this study will also look at the association of C-reactive protein/albumin ratio (CAR) which is an inflammation-based index used in predicting outcomes in a variety of illnesses (sepsis, small cell lung cancer, pancreatic cancer, etc) and has recently been found to be an independent risk factor for mortality in patients with traumatic brain injury, ischemic stroke, and ICH [22-24]. We look to further investigate the relationship between CAR and the severity of intracerebral hemorrhage.

Materials And Methods

Study design
We conducted a retrospective review of a prospectively collected database of patients admitted to the neurosurgery service at Arrowhead Regional Medical Center from 2015 to 2020 with a diagnosis of spontaneous ICH or intraventricular hemorrhage (IVH). In addition to the standard of care, patients had the following labs drawn on admission: TNF-α, CRP, Hcy, and VEGF. CAR was calculated in patients with CRP and albumin drawn on admission. Patients were included in the study if older than age 18, had a diagnosis of spontaneous intracerebral or intraventricular hemorrhage without underlying trauma, vascular abnormality, or evidence of hemorrhagic transformation of ischemic stroke, and if they had at least one of previously mentioned biomarkers drawn on admission for intracerebral hemorrhage. A total of 99 patients were included in the study. Primary outcomes included death, early neurologic decline (END), and hemorrhage size. Secondary outcomes included late neurologic decline (LND), Glasgow Coma Scale (GCS) on admission, GCS on discharge, ICH score, change in hemorrhage size, need for surgical intervention, and length of intensive care unit (ICU) stay.

All patients were admitted to ICU for a minimum of 24 hours with neurological checks every hour. Patients were intubated at the discretion of emergency department or if GCS<8. Systolic blood pressure was strictly maintained with the goal of <140 mmHg. External ventricular drain (EVD) placement occurred if GCS <=8, extensive intraventricular involvement, symptomatic hydrocephalus, or need for use of intraventricular tissue plasminogen activator (t-PA) administration. Some patients underwent bedside intraparenchymal hematoma evacuation and drain placement or craniectomy versus craniotomy, depending on size of hemorrhage, midline shift, patient’s clinical exam, and clinician discretion. Repeat CT head was obtained six to eight hours from initial CT scan to evaluate for change in the size of hematoma. Volume of hemorrhages was calculated via ABC/2 formula [25]. A single neurosurgery resident calculated hemorrhage volume for initial and repeat CT scan. Vascular studies were obtained if underlying vascular abnormalities were suspected. TNF-α, CRP, Hcy, and VEGF levels were determined on admission for hemorrhagic stroke. The labs were performed via Quest Diagnostics. Early neurologic decline was defined as a decrease in GCS of 2 or more points within 48 hours of admission. Late neurologic decline was defined as a decrease of 2 or more GCS points after 48 hours after admission.

Statistical analysis

Descriptive statistics were presented as frequencies and proportions for categorical variables. Chi-squared, odds ratio (OR), and Pearson correlation coefficient were used in analyzing the data. All statistical tests were two-sided. P-values <0.05 were considered to be statistically significant.

Results

A total of 99 patients were included in this study, with 42% requiring surgical intervention, including EVD placement, and an overall mortality of 16%. The surgical procedures performed, and patient demographics are listed in Table 1. Early neurological decline was observed in 10 patients and late neurological decline was seen in 13 patients with both being significantly correlated with mortality (Table 2). The most common hemorrhage occurred in the basal ganglia (41%) as seen in Table 1. GCS on admission was negatively correlated with mortality, while ICH score, presence of IVH, initial ICH size, repeat ICH size, change in ICH size, END, LND, midline shift, and presence of surgical procedure were all positively correlated with mortality (Table 2). None of the four markers or the CAR was significantly correlated with mortality although TNF-α and VEGF had weak non-significant correlations (Table 2). With regards to ICH size, TNF-α, Hcy, and CAR were all weakly correlated with ICH size although this was not significant (r=0.12, r=0.12, r=0.20, respectively). There was a weak negative correlation between VEGF and ICH size although this was not significant (r=-0.18). TNF-α and VEGF were mildly correlated with hemorrhage size in basal ganglia patients, although non-significantly (r=0.32, p=0.08; r=0.21, p=0.26, respectively), while Hcy and CAR were significantly correlated with ICH size in basal ganglia patients (r=0.36, p=0.05; r=0.45, p=0.03, respectively). There was no significant correlation between the markers in ICH size in lobar hemorrhage, although TNF-α was mildly correlated (r=0.31, p=0.12).
|                         |       |
|-------------------------|-------|
| Number of Patients      | 99    |
| Male/Female             | 54/45 |
| Age (range)             | 61.8 (21-88) |
| GCS on admission (range)| 11.9 (5-13) |
| ICH Score (30 day mortality): 0 (0%), 1 (13%), 2 (26%), 3 (27%), 4 (57%), 5 (10%) | |
| 0=26 (3.8% mortality), 1=39 (7.6% mortality), 2=15 (20% mortality), 3=7 (14.3% mortality), 4=11 (64% mortality), 5=1 (100% mortality) |
| ICH Location            | Basal ganglia (41 patients), Lobar (35 patients), Thalamus (10 patients), Cerebellum (6 patients), Caudate (3 patients), Brainstem (2 patients), Intraventricular only (2 patients) |
| Length of ICU Stay      | 6.02 days |
| Early Neurological Decline | 10/99 |
| Late Neurological Decline | 13/99 |
| Mean Intracerebral Hemorrhage Volume (ml) | Initial-25.3 ml, Repeat-23.8 ml, Change-1.5 ml |
| Presence of Intraventricular Hemorrhage | 27/99 |
| Number of Procedures    | 42 procedures: 26 external ventricular drain, 9 intraparenchymal drains, 2 craniectomies, 5 ventriculoperitoneal shunts |
| Midline shift (mm)      | 2.3   |
| Mortality               | 16/99 |

**TABLE 1: Patient demographics, ICH statistics, and surgical interventions**

GCS=Glasgow Coma Score  
ICH=Intracerebral Hemorrhage  
ICU=Intensive Care Unit
### TABLE 2: Factors with correlation to patient mortality

ICH=intracerebral hemorrhage

CAR=CRP:albumin ratio

VEGF=vascular endothelial growth factor

CRP=C-reactive protein

GCS=Glasgow coma scale

TNFα=tumor necrosis factor alpha

CAR was significantly correlated with ICH score (r=0.33, p=0.007874). Patients with admission VEGF levels less than 45 pg/ml had 8.4-fold increase in mortality (OR 8.4545, p=0.0488) (Figure 1). Patient with TNFα levels greater than 1.40 pg/ml had a 4.1-fold increase in mortality (OR 4.1, p=0.04) (Figure 1). There were no significant correlations between the biomarkers tested and END, LND, GCS on admission, GCS on discharge, length of ICU stay, or need for surgical procedure. Four patients were found to have a new hemorrhage during admission, with two of these as a complication of EVD placement. Both patients with post EVD placement hemorrhages died. The two remaining patients with new hemorrhages lived. One patient had a recurrent hemorrhage two months after initial presentation and died.
Discussion

Our study demonstrated that low levels of VEGF (<45 pg/ml) on admission significantly increased mortality by 8.4-fold. This finding adds to our previous study showing that low levels were associated with mortality [21]. It is also consistent with Sobrino et al. (2009), which showed that high levels (>330 pg/ml) of VEGF at 72 hours were associated with improved outcome in patients with intracerebral hemorrhage. This indicates that VEGF is neuroprotective in patients with intracerebral hemorrhage, which is further supported by findings in prior animal studies [26]. In a mouse study, VEGF-induced stem cell administration has been shown to increase angiogenesis and result in improved functional outcome [26]. This increase in angiogenesis likely reduces cerebral ischemia in intracerebral hemorrhage as it has been shown to in ischemic stroke rat studies [27]. In one rat study, intracerebroventricular injection of VEGF was shown to increase angiogenesis and decrease cerebral ischemia while intravenous injection of VEGF increased cerebral infarct volume [27].

Currently, there are no published studies on administration of VEGF or induction of VEGF during intracerebral hemorrhage in humans. This is a promising potential therapeutic modality that could be applied to intracerebral hemorrhage and warrants further research.

TNFα is a pro-inflammatory cytokine release by neuronal macrophages, astrocytes, and microglial cells during intracerebral hemorrhage. This leads to increased release of oxidase and proteases that result in secondary brain injury [5,28]. Prior studies demonstrate that TNFα is associated with worse outcome and mortality in intracerebral hemorrhage [2,6,20]. Our study found TNFα levels to be mildly correlated with ICH size, but this was not significant. However, patients with a TNFα level on admission greater than 1.40 pg/ml were found to have a 4.1-fold increase in mortality. Potential treatments for intracerebral hemorrhage aimed at reducing TNFα levels include anti-TNFα monoclonal antibodies and atorvastatin [26]. Blocking endogenous TNFα via monoclonal anti-TNFα antibodies in rats has been shown to decrease cerebral ischemia [29]. Ewen et al. (2013) demonstrated that atorvastatin induced a dose–dependent reduction of TNFα in plasma and brain tissue in rats with intracerebral hemorrhage and an increase in interleukin 10 (IL-10) which has anti-inflammatory functions. This resulted in a decrease in hemispheric water content, decrease infiltration of leukocytes and microgla, and improvement in neurological deficits among rats treated with atorvastatin [28]. Statin in therapy in ischemic stroke prevention and treatment is well documented in the literature while the benefits of continuation or initiation of statins after ICH is still being investigated [30]. Our study supports the initiation and continuation of statin therapy in hemorrhagic stroke. Once statin therapy is initiated, longer-term follow up could study the effects on functional outcome, recurrance of hemorrhagic stroke, and rates of development of any kind of stroke in the future.

Hcy is not released due to intracerebral hemorrhage but as a result of genetic conditions, vitamin B deficiencies, smoking, high methionine diet, and sedentary lifestyles [11]. Elevated levels have been shown to increase risk of hemorrhage stroke [12]. Our prior study showed a trend toward elevated homocysteine and increase hemorrhage size while our current study confirmed that elevated levels of homocysteine are associated with larger basal ganglia hemorrhages. This was also demonstrated in other prior studies.
CRP is increased in response to acute inflammation, leads to cell apoptosis, and has been shown in previous studies to be a predictor of mortality and associated with worse outcomes after intracerebral hemorrhage [9,10,22]. In our study, CRP was the most commonly elevated of the markers (50% of patients tested) but only showed a mild non-significant correlation with ICH score. However, our study failed to show any relationship between elevated CRP and our primary or secondary outcomes. In order to look further at the relationship of CRP with intracerebral hemorrhage, we evaluated the CAR, which has been used in predicting outcomes in a variety of illnesses (sepsis, small cell lung cancer, pancreatic cancer, etc) and has recently been found to be an independent risk factor of mortality in patients with traumatic brain injury and ischemic stroke [22,23]. This ratio reflects the combined effects of nutrition and inflammation with elevated CAR representing increased inflammation with low nutrition status [22]. Our study demonstrated that CAR was moderately correlated with ICH score and hemorrhage size in patients with basal ganglia hemorrhages but not with mortality. However, both ICH score and hemorrhage size were independently correlated with mortality. Only one other study has evaluated CAR in intracerebral hemorrhage. Bender et al. (2020) reviewed 379 patients with intracerebral hemorrhage and found that CAR levels greater than 1.22 were significantly associated with mortality [24]. Optimizing nutritional status in patients with ICH in addition to CRP lowering therapy (vitamin C, angiotensin-converting enzyme inhibitors, cyclooxygenase inhibitors, etc) is a potential way to mitigate these effects or poses a potential therapeutic avenue to be studied [21]. Further studies into modulating CAR after the onset of hemorrhagic stroke can be studied to evaluate the utility of modifying CRP and albumin in an inpatient setting, rather than only as a preventative measure.

Limitations

One of the biggest limitations of our study is that patients presenting to our institution with intracerebral hemorrhages deemed “catastrophic” or where family elect to pursue “comfort” measures in the emergency department are not admitted to the neurosurgery service. In these patients, the above biomarkers were not drawn by the emergency department or admitting medical service. Thus, our study missed the opportunity to evaluate these biomarkers in some patients with the most severe intracerebral hemorrhages. Another limitation is that not all of the biomarkers and the CAR were available for all of the 99 patients as TNFα was available in 71 patients, Hcy in 72 patients, CRP in 85 patients, VEGF in 74 patients, and CAR in 63 patients. As many of these laboratory markers are send-out studies, it is difficult to ensure that admission blood samples are both sent and tested appropriately; samples could be lost in transit, deemed insufficient, or have other issues resulting in lack of results. This could have limited the effectiveness of our study to obtain associations with these markers. Lastly, there was no long-term follow-up after patients were discharged from the hospital. Developing a follow-up system in conjunction with our internal and family medicine colleagues could mitigate this issue, along with providing better overall medical care for patients.

Conclusions

Our study demonstrated that low levels (<45 pg/ml) of VEGF were associated with an 8.4-fold increase in mortality, supporting the neuroprotective effect of this protein. Elevated Hcy and CAR levels were associated with an increase in hemorrhage size in patients with basal ganglia hemorrhages. TNFα levels greater than 1.40 pg/ml were associated with a 4.1-fold increase in mortality, and this together with CAR being correlated with increased hemorrhage size and ICH score further demonstrate the inflammatory consequences after intracerebral hemorrhage. Future studies directed at lowering CRP, TNFα, and Hcy and/or increasing VEGF in intracerebral hemorrhage patients are needed and may be beneficial. Furthermore, studies aimed at lowering these values in high-risk patients prior to intracerebral hemorrhage should also be evaluated as a potential preventative measure.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. Arrowhead Regional Medical Center issued approval Protocol #20–27. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
Barone F, Arvin B, White R, et al.: Hemorrhage. Atorvastatin involves suppression of TNF alpha and upregulation of IL-10 in a rat model of intracerebral ischemia without increasing blood-brain permeability when administered intracerebroventricularly. Ewen T, Qiuting L, Chaogang T, Tao T, Jun W, Liming T, Guanghong X: Ischemia biomarkers with poor outcome in acute ischemic stroke. Kaya D, Gursoy-Ozdemir Y, Yemisci M, Tuncer N, Aktan S, Dalkara T: Angiogenesis and functional recovery in mouse stroke model. Lee HJ, Kim KS, Park IH, Kim SU: Intracerebral hemorrhage volumes. Kothari R, Brott T, Broderick J, Barsan W, Sauerbeck L, Zuccarello M, Khoury J: Intra-hospital mortality among patients with spontaneous intracerebral hemorrhage. Bender M, Haferkorn K, Friedrick M, Uhl E, Stein M: 10.5603/PJNNS.a2019.0020 Day mortality in patients with acute ischemic stroke. Kocaturk M, Kocaturk O: Patients with traumatic brain injury. Wang R, He M, Ou X, Xie X, Kang Y: Cureus. 2018, 10:3529. Bernstien J E, Savla P, Dong F, et al.: CRP Albumin ratio is positively associated with poor outcome in patients with traumatic brain injury. Clinic Neurol Neurosurg. 2020, 195:106051. 10.1016/j.clineuro.2020.106051

1. Castillo J, Davalos A, Alvarez-Sabin J, et al.: Molecular signatures of brain injury after intracerebral hemorrhage. Neurology. 2002, 58:624-629. 10.1212/WNL.58.4.624
2. Senn R, Elkind M, Montaner J, Christ-Grain M, Katan M: Potential role of blood biomarkers in the management of non-traumatic intracerebral hemorrhage. Cerebrovasc Dis. 2014, 38:595-409. 10.1159/000364470
3. Tuttotolomondo A, Di Raimondo D, di Sciaccia R, Pinto A, Licata G: Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des. 2008, 14:3574-3589. 10.2174/13816120878684739
4. Welsh P, Lowe G, Chalmers J, et al.: Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke. 2008, 39:2226-2230. 10.1161/STROKEAHA.107.504498
5. Rothstein L, Jickling G: Ischemic biomarkers in blood. Biomark Med. 2013, 7:57-47. 10.2217/bmm.12.194
6. Silva V, Leira R, Tejeda J, Lainez J, Castillo J, Davalos A: Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke. 2005, 36:86-91. 10.1161/01.STR.000014615.51204.0b
7. Welsh P, Barber M, Langhorne P, Rumley A, Lowe G, Scott D: Association of inflammatory and haemostatic biomarkers with poor outcome in acute ischemic stroke. Cerebrovasc Dis. 2009, 27:247-253. 10.1159/000196825
8. Napoli D, Papa F, Boccola V: C-Reactive protein in ischemic stroke. Stroke. 2001, 32:917-924. 10.1161/01.STR.32.4.917
9. Napoli M, Godoy D, Campi V, et al.: C-reactive protein level measurement improves mortality prediction when added to the spontaneous intracerebral hemorrhage score. Stroke. 2011, 42:1230-1236. 10.1161/STROKEAHA.110.604985
10. Rajapathy SK, Idhra Z, Kundasamy R, Wong A, Abdulla M: Inflammatory biomarkers and their value in predicting survival and outcome among patients with intracerebral hemorrhage. Malays J Med Sci. 2017, 24:51-65. 10.3135/1/mjmms2017.24.5.7
11. Zhou Z, Liang Y, Qu H, Zhao M, Guo F, Zhao C, Teng W: Plasma homocysteine concentrations and risk of intracerebral hemorrhage: a systemic review and meta-analysis. Sci Rep. 2018, 8:2560-2568. 10.1038/s41598-018-21019-3
12. Saposnik G, Ray J, Sheridan P, McQueen M, Lonn E: Homocysteine-lowering therapy and stroke risk, severity, and disability. Stroke. 2009, 40:1363-1372. 10.1161/STROKEAHA.108.529303
13. Zhou F, Chen B, Chen C, Huang J, Chen S, Guo F, Hu Z: Elevated homocysteine levels contribute to larger hematoma volume in patients with intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2015, 24:784-788. 10.1016/j.jstrokecerebrovasdis.2014.11.005
14. Kwon H, Lee Y, Bae H, Kang D: Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. Stroke. 2014, 45:871-873. 10.1161/STROKEAHA.113.004099
15. Sacco R, Anand K, Lee H, Boden-Alba B, Stabler S, Allen R, Paik M: Homocysteine and the risk of ischemic stroke in a triennial cohort, the northeastern manhattan study. Stroke. 2004, 35:2265-2269. 10.1161/01.STR.0000142574.33919.e2
16. Slevin M, Krupinski J, Slowik A, Kumar P, Szczudlik A, Gaffney J: Serial measurement of vascular endothelial growth factor and transforming growth factor-b1 in serum of patients with acute ischemic stroke. Stroke. 2000, 31:1863-1870. 10.1161/01.STR.31.8.1863
17. Zhang Z, Zhang L, Jiang Q, et al.: VEGF enhances angiogenesis and promotes blood-brain barrier leakage in ischemic brain. J Clin Invest. 2000, 106:829-838. 10.1172/JCI95969
18. Matsumo R, Ago T, Kamouchi M, et al.: Clinical significance of plasma VEGF value in ischemic stroke research for biomarkers in ischemic stroke (REBIOS) study. BMC Neurol. 2013, 13:52. 10.1186/1471-2377-13-52
19. Sobrino T, Arias S, Rodriguez-Gonzalez R, et al.: High serum levels of growth markers are associated with good outcome in intracerebral hemorrhage. J Cereb Blood Flow Metab. 2009, 29:1968-1974. 10.1038/jcbfm.2009.182
20. Yang G, Shao GF: Elevated serum IL-11, TNF alpha, and VEGF expressions contribute to the pathophysiology of hypertensive intracerebral hemorrhage (ICH). Neurol Sci. 2016, 37:1253-1259. 10.1007/s10072-016-2576-z
21. Bernsten J, E, Savla P, Dong F, et al.: Inflammatory markers and severity of intracerebral hemorrhage. Cureus. 2018, 10:5329. 10.7759/cureus.3529
22. Wang R, He M, Ou X, Xie X, Kang Y: CRP Albumin ratio is positively associated with poor outcome in patients with traumatic brain injury. Clinic Neurol Neurosurg. 2020, 195:106051. 10.1016/j.clineuro.2020.106051
23. Kocaturk M, Kocaturk O: Assessment of relationship between C-reactive protein to albumin ratio and 90-day mortality in patients with acute ischemic stroke. Neurol Neurochir Pol. 2019, 53:205-211. 10.5603/PNNS.a2019.0020
24. Bender M, Haferkorn K, Friedrick M, Uhl E, Stein M: Impact of early C-Reactive protein/albumin ratio on intra-hospital mortality among patients with spontaneous intracerebral hemorrhage. J Clin Med. 2020, 9:1236. 10.3390/jcm9041236
25. Kothari R, Brott T, Broderick J, Bursan W, Sauerbeck I, Zuccarello M, Khoury J: The ABC's of measuring intracerebral hemorrhage volumes. Stroke. 1996, 27:1504-1505. 10.1161/01.STR.27.8.1304
26. Lee H, Kim KS, Park IH, Kim SU: Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS ONE. 2007, 2:156. 10.1371/journal.pone.0001516
27. Kayda D, Gursoy-Obzemir Y, Yenimaci M, Tuncer N, Aktan S, Dalkara T: VEGF protects brain against focal ischemia without increasing blood-brain permeability when administered intracerebroventricularly. J Cereb Blood Flow Metab. 2005, 25:1111-1118. 10.1093/jcbfm/600109
28. Ewen T, Quieting L, Chaoqang T, Tao T, Jun W, Liming T, Guanghong X: Neuroprotective effect of atorvastatin involves suppression of TNF alpha and upregulation of IL-10 in a rat model of intracerebral hemorrhage. Cell Biochem Biophys. 2015, 66:337-346. 10.1007/s12015-012-9453-z
29. Barone F, Arvin B, White R, et al.: Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke. 1997, 28:1232-1244. 10.1161/01.STR.28.6.1235
30. Van Matre E, Sherman D, Kiser T: Management of intracerebral hemorrhage-use of statins. Vasc Health Risk Manag. 2016, 12:153-161. 10.2147/VHRM.S75399